Table 2. Relation between Rad51 expression and clinicopathological parameters in 235 cases of NSCL.

	Rad51 (cases and percentage)
Parameters	−a	+b	P-value
Total	240 (70.6%)	100 (29.4%)
Age
⩽59 years	119 (73.5%)	43 (26.5%)	0.269
>59 years	121 (68.0%)	57 (32.0%)
Sex
Male	171 (70.1%)	73 (29.9%)	0.744
Female	69 (71.9%)	27 (28.1%)
T status
1	14 (66.7%)	7 (33.3%)	0.771
2	124 (72.9%)	46 (27.1%)
3	77 (67.5%)	37 (32.5%)
4	25 (71.4%)	10 (28.6%)
N status
0	105 (70.5%)	44 (29.5%)	0.513
1	54 (77.1%)	16 (22.9%)
2	76 (67.3%)	37 (37.2%)
3	5 (62.5%)	3 (37.5%)
M status
0	226 (70.8%)	93 (29.2%)	0.684
1	14 (66.7%)	7 (33.3%)
Stage
I	71 (74.7%)	24 (25.3%)	0.756
II	56 (70.0%)	24 (30.0%)
III	99 (68.8%)	45 (31.3%)
IV	14 (66.7%)	7 (33.3%)
Histology
SCCc	85 (72.6%)	32 (27.4%)	0.891
ADCd	116 (68.6%)	53 (31.4%)
ADSCCe	29 (72.5%)	11 (27.5%)
Othersf	10 (71.4%)	4 (28.6%)
Tumour grade
G1	41 (66.1%)	21 (33.9%)	0.535
G2	109 (66.7%)	52 (33.3%)
G3	90 (76.9%)	27 (23.1%)

^a−=low-level expression of Rad51.

^b+=high-level expression of Rad51.

^cSCC=squamous cell carcinoma.

^dADC=adenocarcinoma.

^eADSCC=adenosquamous carcinoma.

^fothers include anaplastic large-cell carcinoma, sarcoma, adenoid cystic carcinoma, mucoepidermoid carcinoma and carcinoid tumour.